Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
US Army
Healthtrust
Colorcon
Cerilliant
Farmers Insurance
Baxter
Express Scripts
Johnson and Johnson

Generated: November 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 210238

« Back to Dashboard

NDA 210238 describes DOPTELET, which is a drug marketed by Akarx Inc and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the DOPTELET profile page.

The generic ingredient in DOPTELET is avatrombopag maleate. One supplier is listed for this compound. Additional details are available on the avatrombopag maleate profile page.
Summary for 210238
Tradename:DOPTELET
Applicant:Akarx Inc
Ingredient:avatrombopag maleate
Patents:2
Generic Entry Opportunity Date for 210238
Generic Entry Date for 210238*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 210238
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DOPTELET avatrombopag maleate TABLET;ORAL 210238 NDA AkaRx, Inc. 71369-020 71369-020-10 1 BLISTER PACK in 1 CARTON (71369-020-10) > 10 TABLET, FILM COATED in 1 BLISTER PACK (71369-020-11)
DOPTELET avatrombopag maleate TABLET;ORAL 210238 NDA AkaRx, Inc. 71369-020 71369-020-15 1 BLISTER PACK in 1 CARTON (71369-020-15) > 15 TABLET, FILM COATED in 1 BLISTER PACK (71369-020-16)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 20MG BASE
Approval Date:May 21, 2018TE:RLD:Yes
Regulatory Exclusivity Expiration:May 21, 2023
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Try a Free TrialPatent Expiration:May 5, 2025Product Flag?YSubstance Flag?YDelist Request?
Patent:➤ Try a Free TrialPatent Expiration:Jan 15, 2023Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE USING DOPTELET

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
US Army
Farmers Insurance
Cantor Fitzgerald
Fuji
Mallinckrodt
Boehringer Ingelheim
Covington
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.